338 related articles for article (PubMed ID: 10885616)
1. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
5. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia.
Morales A; Arias Salazar J; Salazar Y; García A; Arnoux S; Arancibia A; Deroche C; Rey E
Medicina (B Aires); 2003; 63(3):197-204. PubMed ID: 12876902
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
9. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China.
Zhu FC; Zhou W; Pan H; Lu L; Gerez L; Nauta J; Giezeman K; de Bruijn I
Vaccine; 2008 Aug; 26(35):4579-84. PubMed ID: 18602729
[TBL] [Abstract][Full Text] [Related]
11. [Safety of an influenza-split-vaccine in children].
Schmitt-Grohé S; Banzhoff A; Klaassen B; Zielen S
Klin Padiatr; 2001; 213(6):338-42. PubMed ID: 11713714
[TBL] [Abstract][Full Text] [Related]
12. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
[TBL] [Abstract][Full Text] [Related]
13. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?
Skowronski DM; Tweed SA; De Serres G
J Infect Dis; 2008 Feb; 197(4):490-502. PubMed ID: 18275271
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses after dose-sparing intradermal influenza vaccination.
Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
